Clinical research jobs provider Pfizer has revealed that its commercialisation agreement with Biocon for biosimilar versions of insulin and insulin analog products has been concluded.
It was agreed by the two companies that due to the individual priorities for their respective biosimilars businesses, it would be in their best interest to move forward independently.
However, both parties revealed that they are committed to a smooth transition of the process.
Kiran Mazumdar Shaw, chairman and managing director of Biocon, explained the clinical research firm is going to continue its work with various partners on the treatments.
"Pfizer continues to be dedicated to developing a broad portfolio of biosimilars medicines, including monoclonal antibodies and recombinant proteins products, both internally and through collaborations," added Diem Nguyen, general manager of biosimilars at Pfizer.
Earlier in the month, Pfizer revealed positive results of a project to demonstrate the efficacy of its Phase 3 study of Prevnar 13, which was found to be showing immunogenicity.